Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
Patents for C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
09/2003
09/12/2003WO2003074508A1 Compounds and methods of treating cell proliferative diseases
09/12/2003WO2003074496A1 Halobenzyl substituted phenylaceto esters and amides and use thereof for prevention of harmful organisms
09/12/2003WO2003074475A2 Substituted aryl ketones
09/12/2003WO2003074169A2 Metalorganic catalysts for chemo-, regio- and stereoselective reactions, and corresponding precursors
09/12/2003CA2478482A1 Metalorganic catalysts for chemo-, regio- and stereoselective reactions, and corresponding precursors
09/12/2003CA2477003A1 Compounds and methods of treating cell proliferative diseases
09/11/2003US20030171602 Enantioselective process
09/11/2003US20030171425 Viricides
09/11/2003US20030171400 Rheumatic diseases; osteoporosis; multiple sclerosis; autoimmune disease; joint replacements
09/11/2003US20030171377 Therapy for non-insulin dependent diabetes
09/11/2003US20030171219 2,4,5-trisubstituted phenylketo-enols for use as pesticides and herbicides
09/11/2003US20030170725 Modulation of polyketide synthase gene modules; anticancer agents, fungicide, bactericide
09/10/2003EP1341927A1 Method of preparing 3- 2- (methylsulfonyl)oxy ethoxy]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
09/10/2003EP1341800A2 C-glucosyl ether lipids
09/10/2003EP1157987B1 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
09/04/2003WO2003072103A1 Synthetic derivatives
09/04/2003WO2002088106A3 Cysteine protease inhibitors
09/04/2003US20030166949 Reactrting butyrolactone or valerolactone with formaldehyde;heating under critical temperature, critical pressure
09/04/2003US20030166717 Substituted amide compound containing hydroxy and amino groups; useful for treating Alzheimer's disease and other similar diseases
09/04/2003US20030166668 Substituted heteroarylalkanoic acids
09/03/2003EP1340754A1 Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
09/03/2003EP1340752A1 Process for the production of semi synthetic statins via novel intermediates
09/03/2003CN1439637A Preparation of 3,6-dihydro-2H-pyrane-2-carboxylic ester
09/02/2003US6613942 Glucagon antagonists/inverse agonists
09/02/2003US6613900 Cephalotaxane derivatives and process for their preparation
09/02/2003US6613803 Treating, preventing or ameliorating pain
09/02/2003US6613748 C-glucosyl ether lipids
09/02/2003US6613743 Sulfonamide inhibitors of aspartyl protease
08/2003
08/28/2003WO2003070726A1 Pyranones useful as atm inhibitors
08/28/2003WO2003070719A1 Bryostatin analogues, synthetic methods and uses
08/28/2003WO2003070717A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
08/28/2003WO2003070693A1 Lactic acid derivative
08/28/2003US20030162990 Preparation of nitrogen mustard derivatives
08/28/2003US20030162980 Method for producing 3,4-dihydro-2h-pyran
08/28/2003US20030162814 Amines such as 2-(3-(N-hydroxyamidino)phenylamino)-N-(2'-sulfamoylbiphenyl-4-yl)-2 -methylpropionamide, used as anticoagulants or for prophylaxis of arteriosclerosis, angina pectoris, restinosis or metastasis
08/28/2003US20030162054 Red organic electroluminescent device
08/28/2003CA2480002A1 Lactic acid derivative
08/28/2003CA2473100A1 Pyranones useful as atm inhibitors
08/27/2003EP1338593A1 Process for the preparation of 3,6-dihydro-2H-pyran-2-carbonic acid esters
08/27/2003CN1438999A Serine protease inhibitors
08/26/2003US6610729 Hydroxamic acid derivatives and medicinal utilization thereof
08/23/2003CA2473075A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
08/21/2003WO2003068825A2 Multifunctional monomers and their use in making cross-linked polymers and porous films
08/21/2003WO2003068765A2 Improved process for the production of dihydropyridines
08/21/2003WO2003068183A1 Sunscreen compositions as well as dihydropyridines and dihydropyranes
08/21/2003WO2002032844A8 Epothilone synthesis components iii and iv: asymmetrically substituted acyloins and acyloin derivatives, method for the production thereof and method for the production of epithilone b, d and epothilone derivatives
08/21/2003US20030158430 Via a thermal hetero Diels-Alder reaction from 1,3-dienes and esters of glyoxylic acid
08/21/2003US20030158426 From 4-hydroxy-6-X-substituted-methyl-tetrahydropyran-2-one compounds, where X is a leaving group, with the aid of an acetalization agent, in the presence of an acid catalyst
08/21/2003US20030158423 Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
08/21/2003US20030158422 Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
08/21/2003US20030158250 Agents correcting gene expression regulatory error
08/21/2003US20030158243 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity
08/21/2003CA2476220A1 Improved process for the production of dihydropyridines
08/20/2003EP1053233B1 Hydroxamic and carboxylic acid derivatives
08/20/2003CN1437484A New formulation comprising a beta-blocker and optionally a cholesterol-lowering agent
08/20/2003CN1436775A Process for preparing internal esters
08/20/2003CN1118463C Simple synthesis of 6-methyl-4-hydroxy-2-pyrone
08/19/2003US6608218 Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes
08/19/2003US6608211 Pesticides and herbicides; well tolerated by plants
08/19/2003US6608104 Gem substituted hydroxamic acids
08/19/2003US6608101 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
08/19/2003US6608061 Bisaryl compound and medicament for cancer treatment comprising the same
08/19/2003US6607778 Solid delivery systems for aroma ingredients
08/19/2003US6607677 Optically active butane-1,2,3,4-tetraol derivatives of formula (I). The compounds may be used as doping agents for liquid crystals for a wide range of applications, such as solid state cholesteric filters for projection displays,
08/19/2003CA2099061C Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
08/14/2003WO2003066619A1 Method for purifying simvastatin
08/14/2003WO2003066617A1 Process for producing lactone
08/14/2003WO2003066524A1 Metallized mesoporous silicate and method of oxidation with the same
08/14/2003WO2003065789A2 N-biphenylmethyl aminocycloalkanecarboxamide derivatives
08/14/2003US20030153773 Process for the production of dihydropyridines
08/14/2003US20030153601 A polyhydroxy-polymethyl-8-tridecenoic acid 8-lactone compounds, as antitumor agents, anticarcinogenic agents
08/14/2003US20030153510 Novel compounds inhibiting factor xa activity
08/14/2003CA2473778A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives
08/13/2003EP1334960A1 Process for producing esterificated condensate
08/13/2003EP1165540B1 Tetrahydropyran derivatives and their use as therapeutic agents
08/12/2003US6605747 Reacting the starting material, an alpha , alpha -difluorocyclohexylidene derivative with a halogen to produce an intermediate, reacting the intermediate with a phenol compound in presence of a base
08/12/2003US6605677 Olefin polymerization processes using supported catalysts
08/07/2003WO2003064440A1 Compounds that inhibit factor xa activity
08/07/2003WO2003064378A2 Novel compounds that inhibit factor xa activity
08/07/2003WO2003064369A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003WO2003063797A2 Cycloalkyl inhibitors of potassium channel function
08/07/2003WO2003028662A3 A method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
08/07/2003US20030149294 Process for the preparation of latanoprost
08/07/2003CA2474451A1 Cycloalkyl inhibitors of potassium channel function
08/07/2003CA2473169A1 Compounds that inhibit factor xa activity
08/07/2003CA2473164A1 Novel compounds that inhibit factor xa activity
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/06/2003EP1049537B1 Catalytic compositions and methods for asymmetric allylic alkylation
08/06/2003EP0821674B1 Cyclic amidino agents useful as nitric oxide synthase inhibitors
08/05/2003US6603029 Partially protected trisphenols in which only specifically selected one or two of the three hydroxyl groups are protected with a protecting agent and which are suitable for use as a dissolution inhibitor in chemically amplified photoresists
08/05/2003US6603022 Reacting Lovastatin with a secondary amine under suitable conditions to form the corresponding amide intermediate, methylating the C-8 butyrate side chain, hydrolyzing to free carboxylic acid; lactonization
08/05/2003US6602886 3-alkyl-3-phenyl-piperidines
08/05/2003CA2274375C Process for preparing 3-arylsulfur hydroxamic acids
07/2003
07/31/2003WO2003061660A1 Melanocortin receptor agonists
07/31/2003WO2002094767A3 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
07/31/2003WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses
07/31/2003WO2002020500A3 Materials and methods to potentiate cancer treatment
07/31/2003US20030144523 Epothilone derivatives, method for producing same and their pharmaceutical use
07/31/2003US20030144504 Dialkyl-halogenophenyl-substituted ketoenols
07/31/2003CA2473036A1 Melanocortin receptor agonists
1 ... 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 ... 129